Innovative drugs soothe Fosun Pharma from pain of fading Covid vaccine
With China's pandemic controls ending and the WHO adjusting its vaccination recommendations, demand for the company’s comirnaty vaccine is plunging Key takeaways: Fosun Pharma's net profit fell more than 20%…
Fosun Pharma Hopes Covid Vaccine Can Cure Its Ailing Margins
Company licensed to sell BioNTech’s mRNA vaccine in China reported its revenue rose 28.8% last year, with the Comirnaty vaccine bringing in over $157 million Key takeaways: Fosun Pharma’s revenue…
Recent Articles
RELATED ARTICLES
-
Fosun moves on from debt crisis with renewed focus on tourism, healthcare
0656.HK -
Fosun Tourism travels back to home base with delisting plan
1992.HK 0656.HK
-
Dispute over Covid vaccines casts doubt on Clover Bio recovery
2197.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK
